Katy Beckermann, Medical Director of GU Clinical Research at Tennessee Oncology, shared on X:
“Adding a third drug to pembro plus lenvatinib in first-line clear cell RCC brought toxicity, not increased efficacy.
LITESPARK-012 added either belzutifan or quavonlimab, an anti-CTLA-4 coformulated with pembro, to the doublet.
- Median PFS 20.8 mo with belzutifan and 20.7 mo with quavonlimab vs 23.7 mo on the doublet
- OS HR 1.04 and 1.12, both primary endpoints missed in 1,688 patients
- Discontinuation of any drug for AEs: 51.6% belzutifan arm, 51.4% quavonlimab arm, 36.2% doublet
- The doublet arm control performed as expected
Was it failure of drug exposure again? Do we need novel mechanisms without overlapping toxicity? Huge effort congrats to the team.”
Title: Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study
Authors: Brian I. Rini, Toni K. Choueiri, Martin H. Voss, Mauricio Burotto, Jan Oldenburg, Howard P. Gurney, Thomas R. Ferguson, Hans Hammers, Laurence Albiges, Yüksel Ürün, Roberto I. Romero Diaz, Mustafa Özgüroğlu, Patricio Yañez Weber, Elena Verzoni, Camillo Porta, Alexandra Drakaki, Jun Guo, Nobuaki Matsubara, Aiying Chen, Joseph E. Burgents, Karla G. Rodriguez-Lopez, Thomas B. Powles
You can also read:
